The drug, called Paxlovid, was given to non-hospitalized COVID-19 patients at high risk of progressing to severe illness and was most effective when given within three days of symptom onset. The results are based on a phase ⅔ study, in which there were no deaths in the group that received Paxlovid compared to 10 deaths in the placebo group.
Pfizer said it plans to submit an application for emergency use authorization of Paxlovid as soon as possible and will cease further enrollment of the study due to the overwhelming efficacy.
“Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections and eliminate up to nine out of ten hospitalizations,” Albert Bourla, PhD, Pfizer’s CEO, said in a news release.
Read Pfizer’s full news release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
